Φορτώνει......
Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
Two multicenter, single‐arm, single‐infusion, open‐label studies were conducted to evaluate the effect of ketoconazole (a strong CYP3A inhibitor) or rifampin (a strong CYP3A inducer) daily for 5 days on the pharmacokinetics (PK) and safety of romidepsin (8 mg/m(2) intravenous 4‐hour infusion for the...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Clin Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5034805/ https://ncbi.nlm.nih.gov/pubmed/26053962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.560 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|